Site icon pharmaceutical daily

Bavarian Nordic A/S – Report on the Results of the Annual General Meeting, held April 20, 2021

COPENHAGEN, Denmark, April 20, 2021 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today held the Annual General Meeting with the results as follows: The Annual Report for 2020 was adopted. The Board of Directors’ proposal to transfer the Company’s result to next year was also adopted.The Remuneration Report for 2020 was approved.The General Meeting adopted a resolution to discharge the Board of Directors and the Board of Management from their obligations.Gerard van Odijk, Anders Gersel Pedersen, Erik G. Hansen, Peter Kürstein, Frank Verwiel, Elizabeth McKee Anderson and Anne Louise Eberhard were re-elected to the Board of Directors. The Board of Directors constituted itself with Gerard van Odijk as Chairman and Anders Gersel Pedersen as Deputy Chairman.  Deloitte Statsautoriseret Revisionspartnerselskab was re-elected as auditors. The proposal to increase and extend the Board of Directors’ authorization to increase the share capital of the Company was adopted.The proposal to increase and extend the Board of Directors’ authorization for issuing warrants was adopted. The proposal to amend the Remuneration Policy was adopted.The proposed remuneration of the Board of Directors and the Board Committees for the current financial year was approved.The proposal to authorize the Board of Directors on behalf of the Company to purchase own shares in the Company was adopted. About Bavarian NordicBavarian Nordic is a fully integrated vaccines company focused on the development, manufacture and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Strategic National Stockpile of a non-replicating smallpox vaccine, which has been approved by the FDA under the trade name JYNNEOS®, also for the protection against monkeypox. The vaccine is approved as a smallpox vaccine in Europe under the trade name IMVANEX® and in Canada under the trade name IMVAMUNE®. Our commercial product portfolio furthermore contains the market-leading vaccine Rabipur®/RabAvert® against rabies and Encepur® against tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an Ebola vaccine, MVABEA®, which is licensed to the Janssen Pharmaceutical Companies of Johnson & Johnson. We are also committed to the development of a next generation COVID-19 vaccine based on an in-licensed capsid virus-like particle technology. The vaccine candidate, ABNCoV2, is currently being investigated in clinical trials. For more information visit ContactsEurope: Rolf Sass Sørensen, Vice President Investor Relations, Tel: +45 61 77 47 43US: Graham Morrell, Paddock Circle Advisors,, Tel: +1 781 686 9600 Company Announcement no. 16 / 2021


Exit mobile version